Text Size

Ocular pharmacokinetic/pharmacodynamic modeling for timolol in rabbits using a telemetry system

Sakanaka K., Kawazu K., Tomonari M., Kitahara T., Nakashima M., Nishida K., Nakamura J., Sasaki H., Higuchi S.


  • 2008
  • Biological and Pharmaceutical Bulletin
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Santen Pharmaceutical Co., Ltd., Nara Research and Development Center, 8916-16 Takayama-cho, Ikoma 630-0101, Japan; Department of Hospital Pharmacy, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan; Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan; Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Related Publications

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Esaki Y., Katsuta O., Kamio H., Noto T., Mano H., Iwamura R., Yoneda K., Odani-Kawabata N., Morishima K., Shams N.K.


In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models

Liang H., Baudouin C., Daull P., Garrigue J.-S., Buggage R., Brignole-Baudouin F.


A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models

Daull P., Buggage R., Lambert G., Faure M.-O., Serle J., Wang R.-F., Garrigue J.-S.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022